Page 54 - Read Online

Page 16 of 19 Casadei et al. J Cancer Metastasis Treat 2022;8:21 https://dx.doi.org/10.20517/2394-4722.2022.05

13. Okosun J, Bödör C, Wang J, et al. Integrated genomic analysis identifies recurrent mutations and evolution patterns driving the
initiation and progression of follicular lymphoma. Nat Genet 2014;46:176-81. DOI PubMed PMC
14. Morin RD, Mendez-Lago M, Mungall AJ, et al. Frequent mutation of histone-modifying genes in non-Hodgkin lymphoma. Nature
2011;476:298-303. DOI PubMed PMC
15. Kridel R, Chan FC, Mottok A, et al. Histological Transformation and Progression in Follicular Lymphoma: A Clonal Evolution
Study. PLoS Med 2016;13:e1002197. DOI PubMed PMC
16. Zhang J, Dominguez-Sola D, Hussein S, et al. Disruption of KMT2D perturbs germinal center B cell development and promotes
lymphomagenesis. Nat Med 2015;21:1190-8. DOI PubMed PMC
17. Ortega-Molina A, Boss IW, Canela A, et al. The histone lysine methyltransferase KMT2D sustains a gene expression program that
represses B cell lymphoma development. Nat Med 2015;21:1199-208. DOI PubMed PMC
18. Zhang J, Vlasevska S, Wells VA, et al. The CREBBP Acetyltransferase Is a Haploinsufficient Tumor Suppressor in B-cell
Lymphoma. Cancer Discov 2017;7:322-37. DOI PubMed PMC
19. Caganova M, Carrisi C, Varano G, et al. Germinal center dysregulation by histone methyltransferase EZH2 promotes
lymphomagenesis. J Clin Invest 2013;123:5009-22. DOI PubMed PMC
20. Mondello P, Tadros S, Teater M, et al. Selective Inhibition of HDAC3 Targets Synthetic Vulnerabilities and Activates Immune
Surveillance in Lymphoma. Cancer Discov 2020;10:440-59. DOI PubMed PMC
21. Sugimoto T, Watanabe T. Follicular Lymphoma: The Role of the Tumor Microenvironment in Prognosis. J Clin Exp Hematop
2016;56:1-19. DOI PubMed PMC
22. Delfau-Larue MH, van der Gucht A, Dupuis J, et al. Total metabolic tumor volume, circulating tumor cells, cell-free DNA: distinct
prognostic value in follicular lymphoma. Blood Adv 2018;2:807-16. DOI PubMed PMC
23. Pastore A, Jurinovic V, Kridel R, et al. Integration of gene mutations in risk prognostication for patients receiving first-line
immunochemotherapy for follicular lymphoma: a retrospective analysis of a prospective clinical trial and validation in a population-
based registry. Lancet Oncol 2015;16:1111-22. DOI PubMed
24. Solal-Céligny P, Roy P, Colombat P, et al. Follicular lymphoma international prognostic index. Blood 2004;104:1258-65. DOI
PubMed
25. Federico M, Bellei M, Marcheselli L, et al. Follicular lymphoma international prognostic index 2: a new prognostic index for
follicular lymphoma developed by the international follicular lymphoma prognostic factor project. J Clin Oncol 2009;27:4555-62.
DOI PubMed
26. Batlevi CL, Sha F, Alperovich A, et al. Follicular lymphoma in the modern era: survival, treatment outcomes, and identification of
high-risk subgroups. Blood Cancer J 2020;10:74. DOI PubMed PMC
27. Huet S, Tesson B, Jais J, et al. A gene-expression profiling score for prediction of outcome in patients with follicular lymphoma: a
retrospective training and validation analysis in three international cohorts. Lancet Oncol 2018;19:549-61. DOI PubMed PMC
28. Casulo C, Byrtek M, Dawson KL, et al. Early Relapse of Follicular Lymphoma After Rituximab Plus Cyclophosphamide,
Doxorubicin, Vincristine, and Prednisone Defines Patients at High Risk for Death: An Analysis From the National LymphoCare
Study. J Clin Oncol 2015;33:2516-22. DOI PubMed PMC
29. Sortais C, Lok A, Tessoulin B, et al. Progression of disease within 2 years (POD24) is a clinically relevant endpoint to identify high-
risk follicular lymphoma patients in real life. Ann Hematol 2020;99:1595-604. DOI PubMed
30. Jurinovic V, Metzner B, Pfreundschuh M, et al. Autologous Stem Cell Transplantation for Patients with Early Progression of
Follicular Lymphoma: A Follow-Up Study of 2 Randomized Trials from the German Low Grade Lymphoma Study Group. Biol
Blood Marrow Transplant 2018;24:1172-9. DOI PubMed
31. Casulo C, Friedberg JW, Ahn KW, et al. Autologous Transplantation in Follicular Lymphoma with Early Therapy Failure: A
National LymphoCare Study and Center for International Blood and Marrow Transplant Research Analysis. Biol Blood Marrow
Transplant 2018;24:1163-71. DOI PubMed PMC
32. Casulo C, Dixon JG, Le-Rademacher J, et al. Validation of POD24 as a robust early clinical end point of poor survival in FL from
5225 patients on 13 clinical trials. Blood 2022;139:1684-93. DOI PubMed
33. Maurer MJ, Bachy E, Ghesquières H, et al. Early event status informs subsequent outcome in newly diagnosed follicular lymphoma.
Am J Hematol 2016;91:1096-101. DOI PubMed PMC
34. Trotman J, Barrington SF, Belada D, et al. Prognostic value of end-of-induction PET response after first-line immunochemotherapy
for follicular lymphoma (GALLIUM): secondary analysis of a randomised, phase 3 trial. Lancet Oncol 2018;19:1530-42. DOI
PubMed
35. Trotman J, Fournier M, Lamy T, et al. Positron emission tomography-computed tomography (PET-CT) after induction therapy is
highly predictive of patient outcome in follicular lymphoma: analysis of PET-CT in a subset of PRIMA trial participants. J Clin
Oncol 2011;29:3194-200. DOI PubMed
36. Meignan M, Cottereau AS, Versari A, et al. Baseline Metabolic Tumor Volume Predicts Outcome in High-Tumor-Burden Follicular
Lymphoma: A Pooled Analysis of Three Multicenter Studies. J Clin Oncol 2016;34:3618-26. DOI PubMed
37. Guadagnolo BA, Li S, Neuberg D, et al. Long-term outcome and mortality trends in early-stage, Grade 1-2 follicular lymphoma
treated with radiation therapy. Int J Radiat Oncol Biol Phys 2006;64:928-34. DOI PubMed
38. Cencini E, Puccini B, Rigacci L, et al. Radiotherapy plus rituximab as first-line regimen for localized follicular lymphoma. Leuk
Lymphoma 2018;59:1420-6. DOI PubMed